Skip to main content
Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

155 wyświetleń
Pobierz
Farmaceutyczny

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Zaawansowana formuła farmaceutyczna do celowanego działania terapeutycznego.

Dawkowanie

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Moc

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Wielkość opakowania

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Postać

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Źródło

European Medicines Agency

Zobacz źródło

Profil bezpieczeństwa

Przeciwwskazania

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Skutki uboczne

Victoza-H-C-1026-PSUSA-00001892-201912: EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Powiązane artykuły kliniczne